The Readout

Moderna’s patent problems & clocking the CRISPR race

By Damian Garde @damiangarde and Meghana Keshavan @megkesh

May 17, 2017

Alex Hogan/STAT

The Readout for May 17, 2017

About the Authors

Damian Garde

National Biotech Reporter

Damian covers biotech and writes The Readout newsletter.

Meghana Keshavan

Biotech Correspondent

Meghana covers biotech and writes The Readout newsletter.

Trending
Pills on chessboard
John Arnold: Are pharmacy benefit managers the good guys…
John Arnold: Are pharmacy benefit managers the good guys or bad guys of drug pricing?
Herpes viruses
Flawed herpes testing leads to many false positives —…
Flawed herpes testing leads to many false positives — and needless suffering
Heroin and Fentanyl doses
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
Recommended
CRISPRing vaccines, alleging price-fixing, & placing blame for insulin…
CRISPRing vaccines, alleging price-fixing, & placing blame for insulin pricing
The READOUT
Drug pricing realpolitik & a (premature) look at IPOs
Drug pricing realpolitik & a (premature) look at IPOs
The READOUT
Dancing fentanyl tubes, & a holiday for generics
Dancing fentanyl tubes, & a holiday for generics

Recommended Stories

The Readout

CRISPRing vaccines, alleging price-fixing, & placing blame for insulin pricing

By Damian Garde

The READOUT
The Readout

Drug pricing realpolitik & a (premature) look at IPOs

By Damian Garde

The READOUT
The Readout

Dancing fentanyl tubes, & a holiday for generics

By Damian Garde

The READOUT
The Readout

The future of NASH & an IPO ‘chess game’

By Damian Garde

The READOUT
The Readout

Gilead’s NASH stumble & the problem with ‘anti-aging’ biotech

By Damian Garde

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy